| Literature DB >> 28962307 |
Yoko Hashimoto1, Mayumi Mori2, Shuichiro Kobayashi3, Akira Hanya4, Shin-Ichi Watanabe5, Naoki Ohara5, Toshihide Noguchi3, Tatsushi Kawai6, Harumi Okuyama5.
Abstract
Canola oil (Can) and hydrogenated soybean oil (H2-Soy) are commonly used edible oils. However, in contrast to soybean oil (Soy), they shorten the survival of stroke-prone spontaneously hypertensive (SHRSP) rats. It has been proposed that the adverse effects of these oils on the kidney and testis are caused at least in part by dihydro-vitamin K (VK) 1 in H2-Soy and unidentified component(s) in Can. Increased intake of dihydro-VK1 is associated with decreased tissue VK2 levels and bone mineral density in rats and humans, respectively. The aim of the present study was to determine the effects of these oils on bone morphogenetic protein (BMP)-induced ectopic bone formation, which is promoted by VK2 deficiency, in relation to the role of VK in the γ-carboxylation of osteocalcin and matrix Gla protein. A crude extract of BMPs was implanted into a gap in the fascia of the femoral muscle in 5-week-old mice maintained on a Soy, Can, or H2-Soy diet. Newly formed bone volume, assessed by three-dimensional X-ray micro-computed tomography and three-dimensional reconstruction imaging for bone, was 4-fold greater in the Can and H2-Soy groups than in the Soy group. The plasma carboxylated osteocalcin (Gla-OC) and total OC (Gla-OC plus undercarboxylated osteocalcin [Glu-OC]) levels were significantly lower in the Can group than in the Soy group (p < 0.05). However, these levels did not significantly differ between the H2-Soy and Soy groups. The plasma Gla-OC/Glu-OC ratio in the Can and H2-Soy groups was significantly lower (in Can; p = 0.044) or was almost significantly lower (in H2-Soy; p = 0.053) than that in the Soy group. In conclusion, Can and H2-Soy accelerated BMP-induced bone formation in mice to a greater extent than Soy. Further research is required to evaluate whether the difference in accelerated ectopic bone formation is associated with altered levels of VK2 and VK-dependent protein(s) among the three dietary groups.Entities:
Keywords: 4056): Vitamin K3 (PubChem CID: 4055); BMP, bone morphogenetic protein; Bone morphogenetic protein; Can, canola oil; Canola oil; Dihydro-vitamin K1 (PubChem CID: 152059); Ectopic calcification; G6PDH, glucose-6-phosphate dehydrogenase; Gla, carboxyglutamic acid; Gla-OC, carboxylated osteocalcin; Glu-OC, undercarboxylated osteocalcin; H2-Soy, hydrogenated soybean oil; Hydrogenated soybean oil; Matrix Gla protein; Osteocalcin; SHRSP rat, stroke-prone spontaneously hypertensive rat; Soy, soybean oil; TRI/3D-BON, three-dimensional reconstruction imaging for bone; VK, vitamin K; Vitamin K; Vitamin K1 (PubChem CID: 52384607); Vitamin K1 hydroquinone (PubChem CID: 5280585); Vitamin K2 (PubChem CID; cMGP, carboxylated matrix Gla protein; dihydro-VK1, 2′, 3′-dihydro-vitamin K1; mCT, micro-computed tomography; ucMGP, undercarboxylated MGP
Year: 2014 PMID: 28962307 PMCID: PMC5598561 DOI: 10.1016/j.toxrep.2014.10.021
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Fig. 1Conversion of vitamin K (VK) 1 to VK2, production of dihydro-VK1, the VK cycle, and γ-glutamyl carboxylation. (A) VK1, but not dihydro-VK1, is enzymatically converted into VK2 (MK-4) via VK3 [15], [16], [20]; VK1 is converted to dihydro-VK1 by the partial hydrogenation process [33]. (B) The active form of VK (VK hydroquinone) is synthesized by the reduction of VK quinone (VK1, VK2, and dihydro-VK1) [20]. (C) Gla proteins are synthesized from Glu proteins by γ-glutamyl carboxylase via a VK hydroquinone-dependent synthesis pathway.
Fig. 2Determination of the ratio of vitamin K (VK) 1 and dihydro-VK1 in the vegetable oils. (A) High performance liquid chromatography (HPLC) analysis of the standard (Std; 5 ng each) and VK homologues eluted from soybean oil (Soy), hydrogenated soybean oil (H2-Soy), and canola oil (Can). The VK1 and dihydro-VK1 content of H2-Soy was estimated from the ratio of peak areas of VK1 and dihydro-VK1 in the H2-Soy eluted from the column. (B) Exploded view of (A) after 10 min.
Fig. 3Newly formed bone in mice fed the soybean oil (Soy), canola oil (Can), or hydrogenated soybean oil (H2-Soy) diet after implantation with a crude extract of bone morphogenetic proteins (BMPs). (A) Representative reconstructed images generated from three-dimensional X-ray micro-computed tomography (3D R_mCT) scans of ectopic newly formed bone (arrow) in the femoral muscle. (B) The volume of newly formed ectopic bone induced by the implantation of the crude extract of BMPs in mice fed the Soy, Can, and H2-Soy diets was calculated from 3D R_mCT scans using three-dimensional reconstruction imaging for bone (TRI/3D-BON).
*p < 0.05 vs. Soy.
Tissue weights of mice fed the soybean oil (Soy), canola oil (Can), and hydrogenated soybean oil (H2-Soy) diets.a
| Weight (g) | Soy | Can | H2-Soy |
|---|---|---|---|
| Body | 40.2 ± 0.8 | 40.2 ± 0.7 | 42.8 ± 1.5 |
| Heart | 0.18 ± 0.003 | 0.18 ± 0.003 | 0.19 ± 0.007 |
| Liver | 1.87 ± 0.10 | 1.65 ± 0.06 | 2.09 ± 0.10 |
| Kidney | 0.58 ± 0.02 | 0.61 ± 0.03 | 0.67 ± 0.02 |
| Testis | 0.20 ± 0.01 | 0.21 ± 0.02 | 0.27 ± 0.01 |
Values are represented as mean ± standard error (SE) (n = 6 per group).
p < 0.05 vs. H2-Soy.
p < 0.01 vs. H2-Soy.
Hepatic glucose-6-phosphate dehydrogenase (G6PDH) activity and total antioxidant power in mice fed the soybean oil (Soy), canola oil (Can), and hydrogenated soybean oil (H2-Soy) diets.a
| Soy | Can | H2-Soy | |
|---|---|---|---|
| G6PDH | 2.10 ± 0.11 | 2.09 ± 0.09 | 2.47 ± 0.11 |
| TAOP | 57.8 ± 3.92 | 55.6 ± 0.85 | 65.7 ± 2.94 |
Values are represented as mean ± SE of duplicate assays (n = 6 per group).
G6PDH: glucose-6-phosphate dehydrogenase (mU/mg protein).
TAOP: total antioxidant power (uric acid equivalent; pmole/mg protein).
p < 0.05 vs. H2-Soy.
p < 0.01 vs. H2-Soy.
Plasma levels of VK-dependent proteins (cMGP, OC, and OC derivatives) in mice fed the soybean oil (Soy), canola oil (Can), and hydrogenated soybean oil (H2-Soy) diets.a
| Soy | Can | H2-Soy | |
|---|---|---|---|
| cMGP (ng/mL) | 113.0 ± 4.9 | 114.9 ± 3.6 | 110.9 ± 4.9 |
| cMGP (ng/mL) | 88.6 ± 11.2 | 101.3 ± 18.4 | 78.7 ± 12.0 |
| Gla-OC (ng/mL) | 89.3 ± 7.9 | 59.0 ± 7.6 | 73.8 ± 8.0 |
| Glu-OC (ng/mL) | 7.00 ± 0.81 | 6.55 ± 0.64 | 7.83 ± 0.82 |
| Total OC (ng/mL) | 96.3 ± 8.0 | 65.5 ± 7.6 | 81.6 ± 8.5 |
| Gla-OC/total OC | 0.93 ± 0.01 | 0.89 ± 0.01 | 0.90 ± 0.01 |
| Gla-OC/Glu-OC | 13.8 ± 1.96 | 9.4 ± 1.34 | 9.6 ± 0.73 |
cMGP, carboxylated MGP; Gla-OC, carboxylated osteocalcin; Glu-OC, undercarboxylated osteocalcin; OC, osteocalcin.
Values are represented as mean ± SE of duplicate assays (n = 6 per group).
Measured using a CBS-E16540m kit (Cusabio Biotech Co., Ltd., Hubei, China).
Measured using a SEB477Mu kit (Cloud-Clone Corp., Houston, TX, USA).
Total OC represents the combined levels of Gla-OC and Glu-OC.
p < 0.05 vs. Soy.
p = 0.044 vs. Soy.
p = 0.053 vs. Soy.